COMP <GO>
RXST vs JNJ // REVENUE GROWTH (YOY)
RxSight Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: RXST 1
— JNJ 9
▲ REVENUE GROWTH (YOY) LEADER: JNJ
LAST: $5.05 (+3.06%) • MKT CAP: $210.0M
revenue-growth
-3.90%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
revenue-growth
6.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RXST VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RXST | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 76.60% | 67.90% | +8.70 | RXST | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -14.90% | 25.50% | -40.40 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -9.21% | 2.97% | -12.18 | JNJ | /fcf-yield <GO> |
| Operating Margin | -35.80% | 34.70% | -70.50 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 28.50% | -28.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | -3.90% | 6.00% | -9.90 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.45 | 5.59 | -4.14 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 8/9 | -6.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.3 | 62.1 | -9.80 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $210.0M | $662.49B | -$662.28B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RXST REV | JNJ REV | RXST GROSS % | JNJ GROSS % | RXST FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $134.5M | $94.19B | 76.6% | 67.9% | -$19.3M | $19.70B |
| FY 2024 | $139.9M | $88.82B | 70.7% | 69.1% | -$22.4M | $19.84B |
| FY 2023 | $89.1M | $85.16B | — | — | -$41.6M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RXST // BETA —
JNJ // BETA 1.08